.jpg?format=webp&width=780)
This study compared outcomes in adults with sub-optimally controlled type 2 diabetes who initiated treatment with iGlarLixi or premixed insulin. The study found that iGlarLixi had significantly higher treatment persistence at 12 months compared to premixed insulin, similar adherence and HbA1c reduction, and numerically lower hypo-glycaemia events, healthcare resource utilization, and costs. These findings were consistent across age and baseline HbA1c subgroups. Therefore, once-daily iGlarLixi is an effective treatment alternative to premixed insulin in people with suboptimally controlled type 2 diabetes.
Like
Save
Share